Your browser doesn't support javascript.
A motley of possible therapies of the COVID-19: reminiscing the origin of the pandemic.
Kaur, Ishnoor; Behl, Tapan; Sehgal, Aayush; Singh, Sukhbir; Sharma, Neelam; Subramanian, Vetriselvan; Fuloria, Shivkanya; Fuloria, Neeraj Kumar; Sekar, Mahendran; Dailah, Hamed Ghaleb; Alsubayiel, Amal M; Bhatia, Saurabh; Al-Harrasi, Ahmed; Aleya, Lotfi; Bungau, Simona.
  • Kaur I; Chitkara College of Pharmacy, Chitkara University, Punjab, India.
  • Behl T; Chitkara College of Pharmacy, Chitkara University, Punjab, India. tapanbehl31@gmail.com.
  • Sehgal A; Chitkara College of Pharmacy, Chitkara University, Punjab, India.
  • Singh S; MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana-Ambala, Haryana, 133207, India.
  • Sharma N; MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana-Ambala, Haryana, 133207, India.
  • Subramanian V; Faculty of Medicine, Bioscience and Nursing, MAHSA University, Jenjarom, Selangor, Malaysia.
  • Fuloria S; Faculty of Pharmacy & Center of Excellence for Biomaterials Engineering, AIMST University, Bedong, Kedah, Malaysia.
  • Fuloria NK; Faculty of Pharmacy & Center of Excellence for Biomaterials Engineering, AIMST University, Bedong, Kedah, Malaysia.
  • Sekar M; Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Health Sciences, Universiti Kuala Lumpur, Royal College of Medicine, Perak, Ipoh, Malaysia.
  • Dailah HG; Research and Scientific Studies Unit, College of Nursing, Jazan University, Jazan, Saudi Arabia.
  • Alsubayiel AM; Department of Pharmaceutics, College of Pharmacy, Qassim University, Buraydah, Kingdom of Saudi Arabia.
  • Bhatia S; Natural & Medical Sciences Research Center, University of Nizwa, Nizwa, Oman.
  • Al-Harrasi A; School of Health Science, University of Petroleum and Energy Studies, Dehradun, Uttarakhand, India.
  • Aleya L; Natural & Medical Sciences Research Center, University of Nizwa, Nizwa, Oman.
  • Bungau S; Chrono-Environment Laboratory, UMR CNRS 6249, Bourgogne Franche-Comté University, Besançon, France.
Environ Sci Pollut Res Int ; 29(45): 67685-67703, 2022 Sep.
Article in English | MEDLINE | ID: covidwho-1982295
ABSTRACT
The 2019 outbreak of corona virus disease began from Wuhan (China), transforming into a leading pandemic, posing an immense threat to the global population. The WHO coined the term nCOVID-19 for the disease on 11th February, 2020 and the International Committee of Taxonomy of Viruses named it SARS-CoV-2, on account of its similarity with SARS-CoV-1 of 2003. The infection is associated with fever, cough, pneumonia, lung damage, and ARDS along with clinical implications of lung opacities. Brief understanding of the entry target of virus, i.e., ACE2 receptors has enabled numerous treatment options as discussed in this review. The manuscript provides a holistic picture of treatment options in COVID-19, such as non-specific anti-viral drugs, immunosuppressive agents, anti-inflammatory candidates, anti-HCV, nucleotide inhibitors, antibodies and anti-parasitic, RNA-dependent RNA polymerase inhibitors, anti-retroviral, vitamins and hormones, JAK inhibitors, and blood plasma therapy. The text targets to enlist the investigations conducted on all the above categories of drugs, with respect to the COVID-19 pandemic, to accelerate their significance in hindering the disease progression. The data collected primarily targets recently published articles and most recent records of clinical trials, focusing on the last 10-year database. The current review provides a comprehensive view on the critical need of finding a suitable treatment for the currently prevalent COVID-19 disease, and an opportunity for the researchers to investigate the varying possibilities to find and optimized treatment approach to mitigate and ameliorate the chaos created by the pandemic worldwide.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Janus Kinase Inhibitors / COVID-19 Type of study: Prognostic study Limits: Humans Language: English Journal: Environ Sci Pollut Res Int Journal subject: Environmental Health / Toxicology Year: 2022 Document Type: Article Affiliation country: S11356-022-22345-w

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Janus Kinase Inhibitors / COVID-19 Type of study: Prognostic study Limits: Humans Language: English Journal: Environ Sci Pollut Res Int Journal subject: Environmental Health / Toxicology Year: 2022 Document Type: Article Affiliation country: S11356-022-22345-w